• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    11/26/24 4:15:35 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email
    false 0001737927 Canopy Growth Corp 00-0000000 0001737927 2024-11-26 2024-11-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): November 26, 2024

     

     

    Canopy Growth Corporation

    (Exact name of registrant as specified in its charter)

     

     

    Canada   001-38496   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    1 Hershey Drive
    Smiths Falls, Ontario
    K7A 0A8
    (Address of principal executive offices) (Zip Code)

     

    (855) 558-9333

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Common Shares, no par value   CGC   Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company    ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Appointment of Luc Mongeau as Chief Executive Officer

     

    On November 26, 2024, the board of directors (the “Board”) of Canopy Growth Corporation (the “Company”) appointed Luc Mongeau, a current member of the Board, to serve as Chief Executive Officer (“CEO”) of the Company (the “Appointment”), effective January 6, 2025 (the “Start Date”). Mr. Mongeau recused himself from the proceedings relating to his appointment. In connection with the Appointment, the Board has also removed Mr. Mongeau as a member of the CGCN Committee and appointed Willy Kruh, an independent director, to the CGCN Committee, effective immediately. Mr. Mongeau will remain a member of the Board.

     

    As previously disclosed, on August 15, 2024, the Company entered into a Mutual Separation Agreement (the “Separation Agreement”) with David Klein, the Company’s current CEO, pursuant to which Mr. Klein will remain as CEO until the earlier of: (i) March 31, 2025, or (ii) the date that a new CEO commences employment. Mr. Klein will continue in his role as CEO and a member of the Board until the Start Date, at which time Mr. Klein will step down from the Board and will serve as Special Advisor to the Board until August 31, 2025. Mr. Klein’s stepping down from the Board will result in a vacancy on the Board, for which the Company is actively seeking candidates.

     

    Mr. Mongeau, 58, served as a Board observer from early 2023 until he became a member of the Board in February 2024. Mr. Mongeau is a seasoned executive with over 25 years of experience spearheading multi-billion-dollar consumer goods companies throughout North America, including Weston Foods, Mars, and Mars Petcare. Since September 2022, Mr. Mongeau has been the CEO of eSolutions Furniture Inc. and was previously the President of Weston Foods Inc. from September 2017 to March 2022. Mr. Mongeau holds a Bachelor of Science from the Université de Sherbrooke and an MBA from the Ivey School of Business at Western University. He has also completed executive education at Harvard Business School.

     

    There are no arrangements or understandings between Mr. Mongeau and any other person pursuant to which he was selected as Chief Executive Officer. Mr. Mongeau does not have any family relationships with any of the Company’s directors, executive officers, or other person nominated or chosen by the Company to become a director or executive officer. There are no transactions between Mr. Mongeau and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

     

    Employment Agreement with Luc Mongeau

     

    In connection with the Appointment, on November 26, 2024, the Company and Mr. Mongeau entered into an employment agreement (the “Employment Agreement”). Pursuant to the Employment Agreement, as CEO, Mr. Mongeau will report to the Board and is entitled to a base salary of CAD$975,000 per year.

     

    Mr. Mongeau is also eligible for a short-term annual incentive performance bonus of 100% of his base salary (the “Target Amount”), with a payout range of up to two times the Target Amount based upon the achievement of certain mutually developed financial, operational, strategic and individual performance objectives approved by the Board.

     

    Mr. Mongeau is also entitled to participate in the Company’s Amended and Restated Omnibus Incentive Plan (the “Incentive Plan”). Pursuant to the Employment Agreement, Mr. Mongeau is eligible to receive, at least once every fiscal year, a long-term award grant equal to 300% of base salary, which may be comprised of stock options (“Options”) and restricted stock units (“RSUs”), and/or any other form of equity authorized by the Incentive Plan.

     

    In connection with the Appointment and pursuant to the Employment Agreement, Mr. Mongeau will be provided with a one-time equity award grant (the “Equity Award”) in the form of 50,000 RSUs and Options to purchase 225,000 common shares of the Company. The Equity Award will be granted on the earliest permitted date following the Start Date, will have a three-year term and will vest in three equal installments on the first, second and third anniversaries of the grant date.

     

     

     

     

    The Company may terminate the Employment Agreement at any time for reasons other than just cause or willful misconduct by providing (a) the greater of (i) 18 months’ notice or payment of base salary (plus applicable vacation pay calculated based on maximum ESA (as defined below) vacation pay entitlement) in lieu of such notice and (ii) the minimum amount of notice or pay in lieu of notice together with any applicable statutory severance (together with applicable vacation pay) in accordance with and limited to the provisions of the Employment Standards Act, 2000 (Ontario) (the “ESA”); (b) 1.5 times the average actual amounts paid as a short-term annual incentive performance bonus during the prior two years; (c) the continuation of benefits for a period of two years from the date of termination; and (d) any statutory severance pay that may be required pursuant to the ESA. As a condition to receiving any payments which exceed the statutory entitlements upon termination without cause, Mr. Mongeau will be required to, among other things, execute a release in favor of the Company. The Company may also terminate Mr. Mongeau’s employment with cause, without notice or severance, in accordance with and limited to the provisions of the ESA.

     

    The Employment Agreement contains certain non-competition and non-solicitation provisions in favor of the Company for a period of 18 months following the termination of the Employment Agreement.

     

    The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K (this “Current Report”).

     

    Item 7.01Regulation FD Disclosure.

     

    On November 26, 2024, the Company issued a press release titled “Canopy Growth Announces Mr. Luc Mongeau as the Company’s Next CEO”, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    The information set forth and incorporated by reference in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information set forth and incorporated by reference in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    10.1   Employment Agreement, effective as of November 26, 2024, between Canopy Growth Corporation and Luc Mongeau.
    99.1   Press Release, dated November 26, 2024.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CANOPY GROWTH CORPORATION
         
      By: /s/ Judy Hong  
        Judy Hong
        Chief Financial Officer

     

    Date: November 26, 2024

     

     

     

    Get the next $CGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    12/22/2021Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Canopy Growth Drives Innovation in High-Demand Segments With Latest Product Launches

      Offerings reflect a focused format strategy in Canada's adult-use market Vapes, high-THC flower, pre-roll joints, and edibles introduced across core brands Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched a series of product innovations targeting Canada's fastest-growing adult-use categories.1 The lineup reflects a focused strategy built around four high-demand formats: vapes, high-THC flower, pre-rolls (including infused), and edibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20

      5/6/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis Brand

      New Brand Features Premium Genetics, Selected for Potency, Terpenes, and Consistency Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched Spectrum Reserve, a new premium medical cannabis brand in Canada. Designed to meet the evolving needs of medical cannabis patients, Spectrum Reserve represents the peak of cannabis cultivation – featuring flower selected for size, potency, and terpene levels through rigorous in-house standards during cultivation and post-harvest. Under this new program, Spectrum Reserve is expected to introduce new strains on a r

      4/2/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Strengthens Balance Sheet with Optional Early Prepayment to Reduce Term Loan by US$100 Million

      Early Prepayment Reduces Annual Interest Expense by US$13 Million, Extends Maturity of Term Loan to September 2027 This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated June 6, 2024 to its short form base shelf prospectus dated February 28, 2025 Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it has made an optional early prepayment under its senior secured term loan (the "Term Loan") in an aggregate principal amount equal to US$100 million at a discounted price of US

      4/1/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Financials

    Live finance-specific insights

    See more
    • The Week in Canadian Press Releases: 10 Stories You Need to See

      A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Feb. 14, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

      2/14/25 6:18:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Reports Third Quarter Fiscal Year 2025 Financial Results

      Strong holiday sales drove Storz & Bickel net revenue growth of 19% year-over-year   Record quarter for Canada medical cannabis with net revenue increasing 16%; international markets cannabis net revenue grew 14% year-over-year    Successfully launched Claybourne infused pre-rolls across Canada, Claybourne rose to #3 market share in the infused pre-roll category in British Columbia and Ontario after 6 weeks in market1 SMITHS FALLS, ON, Feb. 7, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announces its financial results for the third fiscal quarter ended December 31, 2024 ("Q3 FY2025"). All financial information in this press

      2/7/25 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth to Report Third Quarter Fiscal 2025 Financial Results on February 7, 2025

      SMITHS FALLS, ON, Jan. 24, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2025 ended December 31, 2024 before financial markets open on February 7, 2025. Following the release of its third quarter fiscal year 2025 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Judy Hong, CFO on February 7 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://app.webinar.net/yY1K7LrWq9O

      1/24/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yanofsky Theresa sold $1,844 worth of shares (2,004 units at $0.92), decreasing direct ownership by 9% to 20,199 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:17:13 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Lazzarato David Angelo sold $2,764 worth of shares (3,004 units at $0.92), decreasing direct ownership by 12% to 22,886 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:16:37 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Kruh Willy sold $1,851 worth of shares (2,012 units at $0.92), decreasing direct ownership by 18% to 9,272 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:15:15 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    SEC Filings

    See more
    • Canopy Growth Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      4/1/25 7:54:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      2/28/25 5:19:22 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B5 filed by Canopy Growth Corporation

      424B5 - Canopy Growth Corp (0001737927) (Filer)

      2/28/25 5:17:50 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      4/19/24 5:00:49 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      11/3/23 4:30:53 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      7/20/23 4:35:52 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Leadership Updates

    Live Leadership Updates

    See more

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canopy USA Announces Appointment of Mr. M. Brooks Jorgensen as President

      A cannabis and beverage alcohol industry executive with more than 25 years of experience, Mr. Jorgensen will lead the unified Canopy USA organization forward with a focus on driving profitable growth across the U.S. With the completed acquisitions of Acreage, Wana, and Jetty, Canopy USA now enters a new chapter of growth across key segments including flower, edibles, vapes, extracts, and through an established retail presence in high potential markets across the Midwest and Northeast BOULDER, Colo., January 6, 2025 /PRNewswire/ - Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. c

      1/6/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Results of Annual General Meeting

      SMITHS FALLS, ON, Sept. 25, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) is pleased to announce today the voting results from its annual general meeting of shareholders held on September 24, 2024 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 1, 2024 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of the direc

      9/25/24 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Extension of Proxy Voting Deadline for Upcoming Annual General Meeting

      Shareholders now have until September 24, 2024 at 9:00 a.m. (Eastern Time) to submit votes to help ensure a quorum is achieved Your Vote is Important! If you need assistance with voting your shares please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at [email protected] SMITHS FALLS, ON, Sept. 20, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) announced today that it has extended the deadline for the submission of proxies related to its upcoming annual general meeting of shareholders (the "Meeting") to September 24, 2024 at 9:00 a.m. (Eastern time). The Meeting will be held later the same day, at 1:00 p.m.

      9/20/24 4:45:00 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth upgraded by Bernstein

      Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

      4/4/23 9:09:41 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bernstein initiated coverage on Canopy Growth with a new price target

      Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

      11/2/22 6:11:10 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Canopy Growth from Sell to Hold

      10/26/22 7:36:52 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care